The Board - Guard Therapeutics

Johan Bygge

Chairman of the board

Chairman of the board since May 2021. Johan Bygge holds a Master of Science from Stockholm School of Economics.

Previous experience: Chairman of EQT Asia Pacific, COO EQT, CFO Investor AB, Deputy CEO Electrolux, CFO Electrolux. Board member of Anticimex, PSM Ltd, I-Med, ILA Vietnam, Sanitec Oy, Hi3G Scandinavia, Rådet för god sed på Aktiemarknaden, etc.

Other assignments: Chairman of the board of Scandi Standard AB (publ), Regin AB, Arevo AB and Q-Linea AB. Deputy chairman of the board of Tredje AP-fonden (AP3). Board member of Getinge AB, Capman Oyj, Lantmännen ek för. and Riksbankens Jubileumsfond.

Shareholding: 11,314 shares

Independent in relation to the company and its senior management as well as to its major shareholders.

Khatereh Ahmadi

Non-Executive Member of the board

Board member since May 2024. Dr. Khatereh Ahmadi has a PhD in biochemistry from King's College London and held a post-doctoral position at the Ludwig Institute for Cancer Research in London. She also holds an MBA from Henley Management College.

Previous experience: With over 20 years of experience in the pharmaceutical industry, Dr Khatereh Ahmadi currently holds the role of Head of Search and Evaluation Business Development Europe & Middle East at MSD, where she has also been actively involved in business development and licensing in the oncology space in Europe. Prior to joining MSD, she was co-founder and CEO of reViral Ltd, a biotechnology company focused on antiviral therapies. Under her leadership, the company secured a $21 million Series A funding round with investors such as Andera Partners and Orbimed. Dr. Ahmadi also played a critical role in founding the oncology company Piramed Ltd where she became head of business development and negotiated a comprehensive license agreement with Genentech and later acquisition by Roche. Dr. Ahmadi has also been a consultant to a number of companies in the EU and the US in the field of oncology..

Other assignments: Head of Search and Evaluation Business Development Europe & Middle East at MSD

Shareholding: 0 shares

Independent in relation to the company and its senior management as well as to its major shareholders.

Göran Forsberg

Non-Executive Member of the board

Board member since May 2019. Born 1963. Göran Forsberg is a PhD in Biochemistry and Associate Professor.

Previous experience: Göran Forsberg has more than 30 years of experience from pharmaceutical development in both the Biotech industry and in large pharmaceutical companies. He has extensive experience of many different parts of drug development, as well as business development and investor relations. Göran Forsberg served as the CEO of Cantargia AB from 2014 until February 2025. Prior to that, he worked as a business development manager at Active Biotech. Previous experience comes from positions at Pharmacia, KabiGen and the University of Adelaide in Australia and as Board member of Isogenica Ltd.

Other assignments: Chairman of the board of Aventera Antibodies AB. Board member of Mesenkia Therapeutics AB.

Shareholding: 5,161 shares

Independent in relation to the company and its senior management as well as to its major shareholders.